Clinical Trials

Phase 1/2 Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction with Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

NCT05110742 on ClinicalTrials.gov Opens a new window

PI: Chitra Hosing, M.D

Phase 1/2 study of CAR.70- engineered IL15-transduced cord blood-derived NK cells in conjunction with lymphodepleting chemotherapy for the management of relapse/refractory hematological malignances

NCT05092451 on ClinicalTrials.gov Opens a new window

PI: David Marin, M.D.

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

NCT04074746 on ClinicalTrials.gov Opens a new window

PI: Yago Nieto, M.D.

Phase 2 Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Stem Cell Transplant Recipients with BK Infection and JC Virus Infection

NCT02479698 on ClinicalTrials.gov Opens a new window

PI: Amanda Olson, M.D.

Most Closely HLA Matched Allogeneic CMV Specific Cytotoxic T-Lymphocytes (CTL) to Treat CMV Infection after Hemapoietic Stem Cell Transplantation (HSCT)

NCT02210078 on ClinicalTrials.gov Opens a new window

PI: Betul Oran, M.D.

Phase 1/2 Trial of Cord blood-derived NK cells genetically engineered with NY-ESO-1 TCR/IL-15 cell receptor for relapsed/refractory multiple myeloma

NCT06066359 on ClinicalTrials.gov Opens a new window

PI: Muzaffar Qazilbash, M.D.

Phase 1/2 Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

NCT06383572 on ClinicalTrials.gov Opens a new window

PI: Jeremy Ramdial, M.D.

Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T Cells for Therapy of Adenovirus Related Disease in Immunocompromised Patients

NCT03425526 on ClinicalTrials.gov Opens a new window

PI: David Marin, M.D.

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients with Advanced Solid Tumors (TROPIKANA)

NCT06066424 on ClinicalTrials.gov

PI: Ecaterina Dumbrava, M.D.

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

NCT03420963 on ClinicalTrials.gov Opens a new window

PI: Demetrios Petropoulos, M.D.

Phase 1/2 Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients

NCT02661282 on ClinicalTrials.gov Opens a new window

PI: Shiao-Pei Weathers, M.D.

A Phase 1 clinical trial with a window-of-opportunity component of engineered NK cells containing deleted TGF-ßR2 and NR3C1 in recurrent grade 4 astrocytoma (glioblastoma)

NCT04991870 on ClinicalTrials.gov Opens a new window

PI: Shiao-Pei Weathers, M.D.

TROP2 CAR NK cells Plus cetuximab in CRC

NCT06358430 on ClinicalTrials.gov Opens a new window

PI: Maria Morelli, M.D.

A Phase 1b Study of Immunotherapy with ex vivo Pre-Activated and expanded CB-NK cells in combination with Cetuximab, in colorectal cancer patients with minimal residual disease (MRD)

NCT05040568 on ClinicalTrials.gov Opens a new window

PI: Maria Morelli, M.D.

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

NCT05101213 on ClinicalTrials.gov Opens a new window

PI: May Daher, M.D.

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

NCT06660420 on ClinicalTrials.gov Opens a new window

PI: Isabella Glitza Oliva, M.D.

Phase 1/2 study of CAR.70-engineered IL15-transduced cord blood-derived NK cells in conjunction with lymphodepleting chemotherapy for the management of advanced renal cell carcinoma, mesothelioma and osteosarcoma

NCT05703854 on ClinicalTrials.gov Opens a new window

PI: David Hong, M.D.

AD-PluReceptor plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients with Autoimmune Disorders

NCT06434363 on ClinicalTrials.gov Opens a new window

PI: Chitra Hosing, M.D.

Phase 1/2 study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer

NCT05922930 on ClinicalTrials.gov Opens a new window

PI: Amir Jazaeri, M.D.

Phase 1/2b study of adoptive NK expressing an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1

NCT06083883 on ClinicalTrials.gov Opens a new window

PI: Andrew Livingston, M.D.

Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients with Cancer

NCT04742595 on ClinicalTrials.gov Opens a new window

PI: David Marin, M.D.